Differentiated Thyroid Cancer Clinical Trial
Official title:
18F-FDG PET-guided External Beam Radiotherapy in Iodine-refractory Differentiated Thyroid Cancer
Description of the role of a post-operative external beam radiotherapy in patients with differentiated thyroid cancer.
The role of post-operative external beam radiotherapy (EBRT) in differentiated thyroid cancer is still discussed considering the low clinical aggressiveness and the availability of ablative 131Iodine therapy. However, there is a subgroup of tumors which lose the ability to capture Iodine over time. This study wants to describe the role of a post-operative external beam radiotherapy in patients with differentiated thyroid cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02870569 -
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
|
Phase 2 | |
| Completed |
NCT01876784 -
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
|
Phase 3 | |
| Completed |
NCT04971473 -
Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
|
Phase 3 | |
| Recruiting |
NCT04964284 -
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
|
Phase 3 | |
| Recruiting |
NCT05078853 -
Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma
|
||
| Active, not recruiting |
NCT03690388 -
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
|
Phase 3 | |
| Recruiting |
NCT02638077 -
Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China
|
N/A | |
| Recruiting |
NCT01700699 -
Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors
|
N/A | |
| Completed |
NCT03176485 -
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
|
N/A | |
| Recruiting |
NCT04563780 -
The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer
|
||
| Completed |
NCT02278198 -
Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123
|
Phase 1 | |
| Active, not recruiting |
NCT04447183 -
The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
|
Phase 2 | |
| Active, not recruiting |
NCT01263951 -
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
|
Phase 2 | |
| Active, not recruiting |
NCT04940052 -
Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer
|
Phase 3 | |
| Recruiting |
NCT04880798 -
Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer
|
N/A | |
| Recruiting |
NCT05789667 -
Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer
|
||
| Recruiting |
NCT05660954 -
Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
|
Phase 2 | |
| Completed |
NCT00295763 -
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
|
Phase 3 | |
| Recruiting |
NCT04321954 -
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
|
Phase 2 |